QWO
Peakcollagenase clostridium histolyticum-aaes
BLASUBCUTANEOUSSOLUTION
Approved
Jul 2020
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
QWO is a subcutaneous collagenase injection approved for Peyronie's disease, a condition characterized by penile curvature caused by collagen plaque formation. The drug works by enzymatically disrupting and lysing collagen deposits in the plaque, reducing penile deformity and patient burden. It represents a non-surgical, injectable treatment option in a specialty indication with limited therapeutic alternatives.
Peak
Product is at peak commercial maturity with moderate competitive pressure; expect stable-to-declining field team size as market consolidates around Xiaflex.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
QWO represents a peak-stage specialty product with a narrow, male-specific indication and limited growth runway. Career opportunities are concentrated in commercial and managed markets roles focused on defending market share against Xiaflex and preparing for competitive/generic erosion.
Brand ManagerField Sales Representative (Urology/Specialty)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.